Multivariate Brain-Blood Signatures in Early-Stage Depression and Psychosis




Popovic, David; Weyer, Clara; Dwyer, Dominic B.; Griffiths, Sian Lowri; Lalousis, Paris Alexandros; Barnes, Nicholas M.; Vetter, Clara; Neuner, Lisa-Maria; Buciuman, Madalina-Octavia; Sarisik, Elif; Paolini, Marco; Lichtenstein, Theresa; Kambeitz-Ilankovic, Lana; Kambeitz, Joseph; Ruhrmann, Stephan; Chisholm, Katharine; Schultze-Lutter, Frauke; Falkai, Peter; Schiltz, Kolja; Steiner, Johann; Ziller, Michael; Pergola, Giulio; Blasi, Giuseppe; Bertolino, Alessandro; Romer, Georg; Lencer, Rebekka; Dannlowski, Udo; Salokangas, Raimo K. R.; Pantelis, Christos; Brambilla, Paolo; Borgwardt, Stefan; Wood, Stephen J.; Meisenzahl, Eva; Koutsouleris, Nikolaos; Upthegrove, Rachel; PRONIA Consortium

PublisherAmerican Medical Association (AMA)

2025

 JAMA Psychiatry

2168-622X

2168-6238

DOIhttps://doi.org/10.1001/jamapsychiatry.2025.3803

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2842841

https://research.utu.fi/converis/portal/detail/Publication/506336154



Importance  

Inflammation is increasingly implicated in the pathophysiology of mood and psychotic disorders. Integrating blood biomarkers and brain imaging may help uncover mechanistic pathways and guide targeted interventions.

Objective  

To identify shared and distinct multivariate patterns of peripheral inflammation and gray matter volume (GMV) in early-stage depressive and psychotic disorders using a transdiagnostic machine learning approach.

Design, Setting, and Participants  

The naturalistic multicenter PRONIA study was conducted between February 2014 and May 2019 with a follow-up period of up to 36 months; baseline data were analyzed between August 2021 and April 2024. Eight sites, including inpatient and outpatient facilities, in 5 European countries (Germany, Italy, Switzerland, Finland, and the United Kingdom) were included. The study included individuals with recent-onset depression (ROD, n = 163) or psychosis (ROP, n = 177) or clinical high-risk states for psychosis (CHR-P, n = 172), all with minimal medication exposure, and healthy control (HC) individuals (n = 166).

Exposures  

Structural magnetic resonance imaging (MRI), peripheral assays of cytokines (eg, interleukin [IL] 6, IL-1β, tumor necrosis factor [TNF] α, C-reactive protein [CRP], brain-derived neurotrophic factor [BDNF], S100 calcium-binding protein B [S100B]); clinical assessments; neurocognitive testing.

Main Outcomes and Measures  

After data collection, sparse partial least squares was used to identify latent brain-blood signatures. Support vector machine classification evaluated psychosocial and neurocognitive predictors of signature expression using repeated nested cross-validation.

Results  

A total of 678 participants (346 [51.0%] female; median [IQR] age, 24.0 [20.9-28.9] years) were included. Four signatures were identified. A psychosis signature (ρ = 0.27; P = .002) differentiated ROP from CHR-P with elevated IL-6, TNF-α, and reduced CRP, alongside GMV shifts in corticothalamic circuits. A depression signature (ρ = 0.19; P = .02) differentiated ROD from HC individuals with elevated IL-1β, IL-2, IL-4, S100B, and BDNF and GMV reductions in limbic regions. Additional signatures reflected age (ρ = 0.67) and sex or MRI quality (ρ = 0.53). Psychosocial features, including a differential childhood trauma pattern, predicted both the psychosis (balanced accuracy [BAC] = 67.2%) and depression (BAC = 78.0%) signatures. Cognitive performance predicted only the psychosis signature (BAC = 65.1%).

Conclusions and Relevance  

In this study, early-stage depression and psychosis exhibited distinct neurobiological signatures involving immune and neuroanatomical markers, challenging fully dimensional disease models. These signatures are shaped by childhood trauma and cognition and may support biologically informed early interventions.


Dr Popovic was supported by the Else-Kröner-Fresenius-Stiftung through the Clinician Scientist Program Else-Kröner-Fresenius-Stiftung Translational Psychiatry. Dr Falkai was funded by the German Science Foundation, the German Ministry of Science, and the German Ministry of Health. Dr Pantelis was supported by National Health and Medical Research Council Senior Principal Research Fellowship (grants 628386 and 1105825) and European Union-National Health and Medical Research Council (grant 1075379). Dr Koutsouleris was supported through grants from the National Institutes of Health (U01MH124639-01), the German Innovation Fund, the German Federal Ministry of Education and Research, and ERA PerMed. Dr Upthegrove is funded by the Medical Research Council (MR/S037675/1); the National Institutes of Health (1U01MH124631-01), the National Institute for Health and Care Research (NIHRDH-NIHR127700), and the National Institute for Health and Care Research, Oxford Health Biomedical Research Centre. All contributing authors except Drs Steiner, Ziller, and Schiltz were supported by PRONIA, a Collaborative Project funded by the European Union under the 7th Framework Programme (grant 602152).


Last updated on 30/12/2025 10:47:00 AM